1260 results

Insight into the Structural Requirements of Benzothiadiazine Scaffold-based Derivatives as Hepatitis C Virus NS5B Polymerase Inhibitors Using 3D-QSAR, Molecular Docking, and Molecular Dynamics

Hepatitis C virus (HCV) infection is a significant world health threat with frequently ineffective problem existed in the present treatment, thus representing a major unmet medical need. The nonstructural viral protein 5B (NS5B), one of the best-studied polymerase, has emerged as an attractive target for the development of novel therapeutics against hepatitis C virus. In … Continued

https://www.certara.com/publication/insight-into-the-structural-requirements-of-benzothiadiazine-scaffold-based-derivatives-as-hepatitis-c-virus-ns5b-polymerase-inhibitors-using-3d-qsar-molecular-docking-and-molecular-dynamics/

Age Related Changes in Fractional Elimination Pathways for Drugs: Assessing the Impact of Variable Ontogeny on Metabolic Drug-drug Interactions

The magnitude of any metabolic drug-drug interactions (DDIs) depends on fractional importance of inhibited pathway which may not necessarily be the same in young children when compared to adults. The ontogeny pattern of cytochrome P450 (CYP) enzymes (CYPs 1A2, 2B6, 2C8, 2C9, 2C18/19, 2D6, 2E1, 3A4) and renal function were analyzed systematically. Bootstrap methodology was … Continued

https://www.certara.com/publication/age-related-changes-in-fractional-elimination-pathways-for-drugs-assessing-the-impact-of-variable-ontogeny-on-metabolic-drug-drug-interactions/

Pre-clinical Assessment of the Absorption, Distribution, Metabolism, and Excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an Orally Bioavailable Systemic Hedgehog Signaling Pathway Inhibitor

GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide) is a potent, selective Hedgehog (Hh) signalling pathway inhibitor being developed for the treatment of various cancers. The in vivo clearance of GDC-0449 was estimated to be 23.0, 4.65, 0.338, and 19.3 ml min-1 kg-1 in mouse, rat, dog and monkeys, respectively. The volume of distribution ranged from 0.490 in rats to 1.68 … Continued

https://www.certara.com/publication/preclinical-assessment-of-the-absorption-distribution-metabolism-and-excretion-of-gdc-0449-2-chloro-n-4-chloro-3-pyridin-2-ylphenyl-4-methylsulfonylbenzamide-an-orally-bioavailable-systemic/

Differences in Cytochrome P450-mediated Pharmacokinetics Between Chinese and Caucasian Populations Predicted by Mechanistic Physiologically-based Pharmacokinetic Modeling

International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines emphasize the need for better understanding of the influence of ethnicity on drug response to minimize duplication of clinical studies, thereby expediting drug approval. We have developed a Chinese database for the prediction of differences in the population kinetics of drugs mainly metabolized … Continued

https://www.certara.com/publication/differences-in-cytochrome-p450-mediated-pharmacokinetics-between-chinese-and-caucasian-populations-predicted-by-mechanistic-physiologically-based-pharmacokinetic-modelling/

Investigation on Quantitative Structure Activity Relationships and Pharmacophore Modeling of a Series of mGluR2 Antagonists

MGluR2 is G protein-coupled receptor that is targeted for diseases like anxiety, depression, Parkinson’s disease and schizophrenia. Herein, we report the three-dimensional quantitative structure-activity relationship (3D-QSAR) studies of a series of 1,3-dihydrobenzo[ b][1,4]diazepin-2-one derivatives as mGluR2 antagonists. Two series of models using two different activities of the antagonists against rat mGluR2, which has been shown … Continued

https://www.certara.com/publication/investigation-on-quantitative-structure-activity-relationships-and-pharmacophore-modeling-of-a-series-of-mglur2-antagonists/

Pre-clinical Metabolism and Disposition of SB939 (Pracinostat), an Orally Active Histone Deacetylase Inhibitor, and Prediction of Human Pharmacokinetics

The preclinical absorption, distribution, metabolism, and excretion (ADME) properties of Pracinostat [(2E)-3-[2-butyl-1-[2-(diethylamino) ethyl]-1H-benzimidazol-5-yl]-N-hydroxyarylamide hydrochloride; SB939], an orally active histone deacetylase inhibitor, were characterized and its human pharmacokinetics (PK) was predicted using Simcyp® and allometric scaling. SB939 showed high aqueous solubility with high Caco-2 permeability. Metabolic stability was relatively higher in dog and human liver microsomes … Continued

https://www.certara.com/publication/preclinical-metabolism-and-disposition-of-sb939-pracinostat-an-orally-active-histone-deacetylase-inhibitor-and-prediction-of-human-pharmacokinetics/

Pharmacometric Approaches to Guide Dose Selection of the Novel GPR40 Agonist TAK-875 in Subjects with Type 2 Diabetes Mellitus

The G-protein-coupled receptor 40 agonist (GPR40) TAK-875 is being developed as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. Pharmacometric approaches such as model-based exposure-response and meta-analyses were applied to (i) characterize exposure/dose-efficacy responses of TAK-875, (ii) characterize the time course of glycosylated hemoglobin A1c (HbA1c) … Continued

https://www.certara.com/publication/pharmacometric-approaches-to-guide-dose-selection-of-the-novel-gpr40-agonist-tak-875-in-subjects-with-type-2-diabetes-mellitus/

A Series of 18F-labelled Pyridinylphenyl Amides as Subtype-selective Radioligands for the Dopamine D3 Receptor

Synthesis, biological activity, and structure-selectivity relationship (SSR) studies of a novel series of potential dopamine D3 receptor radioligands as imaging agents for positron emission tomography (PET) are reported. Considering a structurally diverse library of D3 ligands, SSR studies were performed for a new series of fluorinated pyridinylphenyl amides using CoMFA and CoMSIA methods. The in … Continued

https://www.certara.com/publication/a-series-of-18f-labelled-pyridinylphenyl-amides-as-subtype-selective-radioligands-for-the-dopamine-d3-receptor/
1 of 126
Back to top